Cargando…

Selective BRAFV600E Inhibitor PLX4720, Requires TRAIL Assistance to Overcome Oncogenic PIK3CA Resistance

Documented sensitivity of melanoma cells to PLX4720, a selective BRAFV600E inhibitor, is based on the presence of mutant BRAF(V600E) alone, while wt-BRAF or mutated KRAS result in cell proliferation. In colon cancer appearance of oncogenic alterations is complex , since BRAF, like KRAS mutations, te...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oikonomou, Eftychia, Koc, Michal, Sourkova, Vladimira, Andera, Ladislav, Pintzas, Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124547/ https://www.ncbi.nlm.nih.gov/pubmed/21738740 http://dx.doi.org/10.1371/journal.pone.0021632

Ejemplares similares

The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors
por: Coperchini, Francesca, et al.
Publicado: (2019)

BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study
por: Makrodouli, Eleni, et al.
Publicado: (2011)

ZAK Inhibitor PLX4720 Promotes Extrusion of Transformed Cells via Cell Competition
por: Maruyama, Takeshi, et al.
Publicado: (2020)

Targeting BRAF(V600E) with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer
por: Nucera, Carmelo, et al.
Publicado: (2011)

IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis
por: Perimenis, Philippos, et al.
Publicado: (2016)

Application of in vivo imaging techniques to monitor therapeutic efficiency of PLX4720 in an experimental model of microsatellite instable colorectal cancer
por: Rohde, Sarah, et al.
Publicado: (2017)

Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo
por: Oikonomou, E, et al.
Publicado: (2007)

Adaptive up-regulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells
por: Basile, Kevin J., et al.
Publicado: (2011)

Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL induced apoptosis in vitro and in vivo
por: Oikonomou, E, et al.
Publicado: (2007)

Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review
por: Andrews, Lily J, et al.
Publicado: (2021)

BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications
por: Oikonomou, Eftychia, et al.
Publicado: (2014)

DNMT3B Oncogenic Activity in Human Intestinal Cancer Is Not Linked to CIMP or BRAFV600E Mutation
por: MacKenzie, Douglas J., et al.
Publicado: (2020)

Gene fusions and oncogenic mutations in MLH1 deficient and BRAFV600E wild-type colorectal cancers
por: Ukkola, Iiris, et al.
Publicado: (2022)

BRAFV600E and KIT immunoexpression in early-stage melanoma
por: Germano, Andressa, et al.
Publicado: (2019)

Sequence of therapies for advanced BRAFV600E/K melanoma
por: Gonzalez-Cao, Maria, et al.
Publicado: (2023)

Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro
por: Car, Iris, et al.
Publicado: (2023)

Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032
por: Su, Xi, et al.
Publicado: (2021)

BRAFV600E Negatively Regulates the AKT Pathway in Melanoma Cell Lines
por: Chen, Brenden, et al.
Publicado: (2012)

Lack of BRAFV600E mutation in stage I and II of colorectal cancer
por: Molaei, Mahsa, et al.
Publicado: (2016)

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent
por: del Bufalo, Francesca, et al.
Publicado: (2014)

The clinical significance of BRAFV600E mutations in pediatric papillary thyroid carcinomas
por: Li, Yangsen, et al.
Publicado: (2022)

Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy
por: Rostami, Elham, et al.
Publicado: (2017)

Overproduction of thrombopoietin by BRAFV600E‐mutated mouse hepatocytes and contribution of thrombopoietin to hepatocarcinogenesis
por: Tanaka, Hiroki, et al.
Publicado: (2019)

Secretome Screening of BRAFV600E-Mutated Colon Cancer Cells Resistant to Vemurafenib
por: Car, Iris, et al.
Publicado: (2023)

Differential impact of BRAFV600E isoforms on tumorigenesis in a zebrafish model of melanoma
por: De Paolo, Raffaella, et al.
Publicado: (2023)

BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells
por: Goulielmaki, Maria, et al.
Publicado: (2016)

Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1
por: Gatalica, Zoran, et al.
Publicado: (2015)

The oxidoreductase p66Shc acts as tumor suppressor in BRAFV600E‐transformed cells
por: Furlan, Tobias, et al.
Publicado: (2018)

FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim‐Chester Disease with the BRAFV600 Mutation
por: Oneal, Patricia A., et al.
Publicado: (2018)

Effects of Withdrawal Rate on the Microstructure of Directionally Solidified GH4720Li Superalloys
por: Qu, Jinglong, et al.
Publicado: (2019)

The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells
por: Jenkins, Molly H., et al.
Publicado: (2015)

Mutation of the PIK3CA oncogene in human cancers
por: Karakas, B, et al.
Publicado: (2006)

BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer
por: Toon, Christopher W, et al.
Publicado: (2014)

BRAFV600E-dependent Mcl-1 stabilization leads to everolimus resistance in colon cancer cells
por: He, Kan, et al.
Publicado: (2016)

Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines
por: Dorris, Emma R., et al.
Publicado: (2016)

BRAFV600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
por: Silver, Jennifer A., et al.
Publicado: (2021)

Cutaneous metastasis of cecum cancer with MSI-high and BRAFV600E mutation: a case report
por: Yunoki, Kosuke, et al.
Publicado: (2021)

Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma
por: Isberner, Nora, et al.
Publicado: (2022)

OR09-4 Novel Murine Models of BrafV600E driven Papillary Thyroid Cancer
por: Casado Medrano, Victoria, et al.
Publicado: (2022)

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
por: Subbiah, Vivek, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_oe581u3sqd8e8lhphdbl1otdtq